Piracetam improves mitochondrial dysfunction following oxidative stress

British Journal of Pharmacology

Volumn 147, Issue 2, 2006, Pages 199-208

  Keil, Uta ^a   Scherping, Isabel ^a   Hauptmann, Susanne ^a   Schuessel, Katin ^a   Eckert, Anne ^a   Müller, Walter E ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Aging; Mitochondrial function; Oxidative stress; Piracetam

Indexed keywords

ADENOSINE TRIPHOSPHATE; BRAIN ENZYME; CASPASE 9; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; NITROPRUSSIDE SODIUM; PIRACETAM; SUPEROXIDE DISMUTASE;

AGED; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BIOSYNTHESIS; BRAIN CELL; CELL FUNCTION; CELL MEMBRANE POTENTIAL; CELL STRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; GROUPS BY AGE; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SERUM;

ADENOSINE TRIPHOSPHATE; AGING; ANIMALS; ANTIOXIDANTS; BRAIN; CASPASE 9; CULTURE MEDIA, SERUM-FREE; FEMALE; HYDROGEN PEROXIDE; MEMBRANE POTENTIALS; MICE; MITOCHONDRIA; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROPRUSSIDE; NOOTROPIC AGENTS; OXIDATIVE STRESS; PC12 CELLS; PIRACETAM; RATS;

EID: 31444436195     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706459     Document Type: Article

References (61)

1. ATABAY, C., CAGNOLI, C.M., KHARLAMOV, E., IKONOMOVIC, M.D. & MANEV, H. (1996). Removal of serum from primary cultures of cerebellar granule neurons induces oxidative stress and DNA fragmentation: protection with antioxidants and glutamate receptor antagonists. J. Neurosci. Res., 43, 465-475.
2. BARACCA, A., SGARBI, G., SOLAINI, G. & LENAZ, G. (2003). Rhodamine 123 as a probe of mitochondrial membrane potential: evaluation of proton flux through F(0) during ATP synthesis. Biochim. Biophys. Acta, 1606, 137-146.
3. BENTUE-FERRER, D., PHILOUZE, V., PAPE, D., REYMANN, J.M., ALLAIN, H. & VAN DEN, D.J. (1989). Comparative evaluation of scavenger properties of exifone, piracetam and vinburnine. Fundam. Clin. Pharmacol., 3, 323-328.
4. BENZI, G., PASTORIS, O., VILLA, R.F. & GIUFFRIDA, A.M. (1985). Influence of aging and exogenous substances on cerebral energy metabolism in posthypoglycemic recovery. Biochem. Pharmacol., 34, 1477-1483.
5. BOSETTI, F., BRIZZI, F., BAROGI, S., MANCUSO, M., SICILIANO, G., TENDI, E.A., MURRI, L., RAPOPORT, S.I. & SOLAINI, G. (2002). Cytochrome c oxidase and mitochondrial F(1)F(0)-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol. Aging, 23, 371-376.
6. BROWN, G.C. & BORUTAITE, V. (2002). Nitric oxide inhibition of mitochondrial respiration and its role in cell death. Free Radic. Biol. Med., 33, 1440-1450.
7. BRUNORI, M., GIUFFRE, A., SARTI, P., STUBAUER, G. & WILSON, M.T. (1999). Nitric oxide and cellular respiration. Cell Mol. Life Sci., 56, 549-557.
8. BUTTERFIELD, D.A., HOWARD, B., YATIN, S., KOPPAL, T., DRAKE, J., HENSLEY, K., AKSENOV, M., AKSENOVA, M., SUBRAMANIAM, R., VARADARAJAN, S., HARRIS-WHITE, M.E., PEDIGO JR, N.W. & CARNEY, J.M. (1999). Elevated oxidative stress in models of normal brain aging and Alzheimer's disease. Life Sci., 65, 1883-1892.
9. CARDOSO, S.M., REGO, A.C., PENACHO, N. & OLIVEIRA, C.R. (2004). Apoptotic cell death induced by hydrogen peroxide in NT2 parental and mitochondrial DNA depleted cells. Neurochem. Int., 45, 693-698.
10. CHRISTEN, Y. (2000). Oxidative stress and Alzheimer disease. Am. J. Clin. Nutr., 71, 621S-629S.
11. COLLINS, T.J., BERRIDGE, M.J., LIPP, P. & BOOTMAN, M.D. (2002). Mitochondria are morphologically and functionally heterogeneous within cells. EMBO J., 21, 1616-1627.
12. COOPER, C.E. (2002). Nitric oxide and cytochrome oxidase: substrate, inhibitor or effector? Trends Biochem. Sci., 27, 33-39.
13. COQ, J.O. & XERRI, C. (1999). Acute reorganization of the forepaw representation in the rat SI cortex after focal cortical injury: neuroprotective effects of piracetam treatment. Eur. J. Neurosci., 11, 2597-2608.
14. CROISILE, B., TRILLET, M., FONDARAI, J., LAURENT, B., MAUGUIERE, F. & BILLARDON, M. (1993). Long-term and high-dose piracetam treatment of Alzheimer's disease. Neurology, 43, 301-305.
15. CROUCH, S.P., KOZLOWSKI, R., SLATER, K.J. & FLETCHER, J. (1993). The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J. Immunol. Methods, 160, 81-88.
16. DOMANSKA-JANIK, K. & ZALESKA, M. (1977). The action of piracetam on 14C-glucose metabolism in normal and posthypoxic rat cerebral cortex slices. Pol. J. Pharmacol. Pharm., 29, 111-116.
17. ECKERT, A., KEIL, U., MARQUES, C.A., BONERT, A., FREY, C., SCHUSSEL, K. & MULLER, W.E. (2003). Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochem. Pharmacol., 66, 1627-1634.
18. ECKERT, G.P., CAIRNS, N.J. & MULLER, W.E. (1999). Piracetam reverses hippocampal membrane alterations in Alzheimer's disease. J. Neural Transm., 106, 757-761.
19. EMERIT, J., EDEAS, M. & BRICAIRE, F. (2004). Neurodegenerative diseases and oxidative stress. Biomed. Pharmacother., 58, 39-46.
20. 3H] Aniracetam binds to specific recognition sites in brain membranes. J. Neurochem., 65, 912-918.
21. FURUNO, T., KANNO, T., ARITA, K., ASAMI, M., UTSUMI, T., DOI, Y., INOUE, M. & UTSUMI, K. (2001). Roles of long chain fatty acids and carnitine in mitochondrial membrane permeability transition. Biochem. Pharmacol., 62, 1037-1046.
22. GABRYEL, B., ADAMEK, M., PUDELKO, A., MALECKI, A. & TRZECIAK, H.I. (2002). Piracetam and vinpocetine exert cytoprotective activity and prevent apoptosis of astrocytes in vitro in hypoxia and reoxygenation. Neurotoxicology, 23, 19-31.
23. GIURGEA, C.E. (1982). The nootropic concept and its prospective implications. Drug Dev. Res., 2, 441-446.
24. GOTTLIEB, E., ARMOUR, S.M. & THOMPSON, C.B. (2002). Mitochondrial respiratory control is lost during growth factor deprivation. Proc. Natl. Acad. Sci. U.S.A., 99, 12801-12806.
25. HEISS, W.D., HEBOLD, I., KLINKHAMMER, P., ZIFFLING, P., SZELIES, B., PAWLIK, G. & HERHOLZ, K. (1988). Effect of piracetam on cerebral glucose metabolism in Alzheimer's disease as measured by positron emission tomography. J. Cereb. Blood Flow Metab., 8, 613-617.
26. HORVATH, B., MARTON, Z., HALMOSI, R., ALEXY, T., SZAPARY, L., VEKASI, J., BIRO, Z., HABON, T., KESMARKY, G. & TOTH, K. (2002). In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine. Clin. Neuropharmacol., 25, 37-42.
27. KEIL, U., BONERT, A., MARQUES, C.A., SCHERPING, I., WEYERMANN, J., STROSZNAJDER, J.B., MULLER-SPAHN, F., HAASS, C., CZECH, C., PRADIER, L., MULLER, W.E. & ECKERT, A. (2004). Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J. Biol. Chem., 279, 50310-50320.
28. KISH, S.J., BERGERON, C., RAJPUT, A., DOZIC, S., MASTROGIACOMO, F., CHANG, L.J., WILSON, J.M., DISTEFANO, L.M. & NOBREGA, J.N. (1992). Brain cytochrome oxidase in Alzheimer's disease. J. Neurochem., 59, 776-779.
29. KROEMER, G. & REED, J.C. (2000). Mitochondrial control of cell death. Nat. Med., 6, 513-519.
30. KROHN, A.J., WAHLBRINK, T. & PREHN, J.H. (1999). Mitochondrial depolarization is not required for neuronal apoptosis. J. Neurosci., 19, 7394-7404.
31. LEUTNER, S., ECKERT, A. & MULLER, W.E. (2001). ROS generation, lipid peroxidation and antioxidant enzyme activities in the aging brain. J. Neural Transm., 108, 955-967.
32. LEUTZ, S., STEINER, B., MARQUES, C.A., HAASS, C., MULLER, W.E. & ECKERT, A. (2002). Reduction of trophic support enhances apoptosis in PC12 cells expressing Alzheimer's APP mutation and sensitizes cells to staurosporine-induced cell death. J. Mol. Neurosci., 18, 189-201.
33. MARQUES, C.A., KEIL, U., BONERT, A., STEINER, B., HAASS, C., MULLER, W.E. & ECKERT, A. (2003). Neurotoxic mechanisms caused by the Alzheimer's disease-linked Swedish amyloid precursor protein mutation: oxidative stress, caspases, and the JNK pathway. J. Biol. Chem., 278, 28294-28302.
34. MIELKE, R., PIETRZYK, U., JACOBS, A., FINK, G.R., ICHIMIYA, A., KESSLER, J., HERHOLZ, K. & HEISS, W.D. (1994). HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern. Eur. J. Nucl. Med., 21, 1052-1060.
35. MIZUNO, Y. & OHTA, K. (1986). Regional distributions of thiobarbituric acid-reactive products, activities of enzymes regulating the metabolism of oxygen free radicals, and some of the related enzymes in adult and aged rat brains. J. Neurochem., 46, 1344-1352.
36. MULLER, W.E., ECKERT, G.P. & ECKERT, A. (1999). Piracetam: novelty in a unique mode of action. Pharmacopsychiatry, 32 (Suppl 1), 2-9.
37. MULLER, W.E., KOCH, S., SCHEUER, K., ROSTOCK, A. & BARTSCH, R. (1997). Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain. Biochem. Pharmacol., 53, 135-140.
38. NAFTALIN, R.J., CUNNINGHAM, P. & AFZAL-AHMED, I. (2004). Piracetam and TRH analogues antagonise inhibition by barbiturates, diazepam, melatonin and galanin of human erythrocyte D-glucose transport. Br. J. Pharmacol., 142, 594-608.
39. NEBOT, C., MOUTET, M., HUET, P., XU, J.Z., YADAN, J.C. & CHAUDIERE, J. (1993). Spectrophotometric assay of superoxide dismutase activity based on the activated autoxidation of a tetracyclic catechol. Anal. Biochem., 214, 442-451.
40. OCHIAI, T., OHNO, S., SOEDA, S., TANAKA, H., SHOYAMA, Y. & SHIMENO, H. (2004). Crocin prevents the death of rat pheochromyctoma (PC-12) cells by its antioxidant effects stronger than those of alpha-tocopherol. Neurosci. Lett., 362, 61-64.
41. O'NEILL, M.J., BLEAKMAN, D., ZIMMERMANN, D.M. & NISENBAUM, E.S. (2004). AMPA receptor potentiators for the treatment of CNS disorders. Curr. Drug Targets, 3, 181-194.
42. PAGLIA, D.E. & VALENTINE, W.N. (1967). Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med., 70, 158-169.
43. PARKER JR, W.D., MAHR, N.J., FILLEY, C.M., PARKS, J.K., HUGHES, D., YOUNG, D.A. & CULLUM, C.M. (1994a). Reduced platelet cytochrome c oxidase activity in Alzheimer's disease. Neurology, 44, 1086-1090.
44. PARKER JR, W.D., PARKS, J., FILLEY, C.M. & KLEINSCHMIDT-DEMASTERS, B.K. (1994b). Electron transport chain defects in Alzheimer's disease brain. Neurology, 44, 1090-1096.
45. PELSMAN, A., HOYO-VADILLO, C., GUDASHEVA, T.A., SEREDENIN, S.B., OSTROVSKAYA, R.U. & BUSCIGLIO, J. (2003). GVS-111 prevents oxidative damage and apoptosis in normal and Down's syndrome human cortical neurons. Int. J. Dev. Neurosci., 21, 117-124.
46. PEUVOT, J., SCHANCK, A., DELEERS, M. & BRASSEUR, R. (1995). Piracetam-induced changes to membrane physical properties. A combined approach by 31P nuclear magnetic resonance and conformational analysis. Biochem. Pharmacol., 50, 1129-1134.
47. RAUCA, C., JANTZE, H. & KRUG, M. (2000). Does fucose or piracetam modify the effect of hypoxia preconditioning against pentylenetetrazol-induced seizures? Brain Res., 880, 187-190.
48. SALETU, B., GRUNBERGER, J. & CEPKO, H. (1986). Pharmacokinetic and -dynamic studies in elderlies with a potential antihypoxidotic/nootropic drug tenilsetam utilizing pharmaco-eeg and psychometry. Drug Dev. Res., 9, 95-113.
49. SALETU, B., HITZENBERGER, G., GRUNBERGER, J., ANDERER, P., ZYHLARZ, G., LINZMAYER, L. & RAMEIS, H. (1995). Double-blind, placebo-controlled, pharmacokinetic and -dynamic studies with 2 new formulations of piracetam (infusion and sirup) under hypoxia in man. Int J. Clin. Pharmacol. Ther., 33, 249-262.
50. SANTENS, P., DE BLEECKER, J., GOETHALS, P., STRIJCKMANS, K., LEMAHIEU, I., SLEGERS, G., DIERCKX, R. & DE REUCK, J. (2001). Differential regional cerebral uptake of (18)F-fluoro-2-deoxy-D-glucose in Alzheimer's disease and frontotemporal dementia at initial diagnosis. Eur. Neurol., 45, 19-27.
51. SARTI, P., GIUFFRE, A., FORTE, E., MASTRONICOLA, D., BARONE, M.C. & BRUNORI, M. (2000). Nitric oxide and cytochrome c oxidase: mechanisms of inhibition and NO degradation. Biochem. Biophys. Res. Commun., 274, 183-187.
52. SASTRE, J., PALLARDO, F.V. & VINA, J. (2003). The role of mitochondrial oxidative stress in aging. Free Radic. Biol. Med., 35, 1-8.
53. SCHEUER, K., ROSTOCK, A., BARTSCH, R. & MULLER, W.E. (1999). Piracetam improves cognitive performance by restoring neurochemical deficits of the aged rat brain. Pharmacopsychiatry, 32 (Suppl 1), 10-16.
54. SCHUESSEL, K., LEUTNER, S., CAIRNS, N.J., MULLER, W.E. & ECKERT, A. (2004). Impact of gender on upregulation of antioxidant defence mechanisms in Alzheimer's disease brain. J. Neural Transm., 111, 1167-1182.
55. SCHUESSEL, K., SCHAFER, S., BAYER, T.A., CZECH, C., PRADIER, L., MULLER-SPAHN, F., MULLER, W.E. & ECKERT, A. (2005). Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice. Neurobiol. Dis., 18, 89-99.
56. STOLL, L., SCHUBERT, T. & MULLER, W.E. (1992). Age-related deficits of central muscarinic cholinergic receptor function in the mouse: partial restoration by chronic piracetam treatment. Neurobiol. Aging, 13, 39-44.
57. SZELIES, B., MIELKE, R., KESSLER, J. & HEISS, W.D. (2001). Restitution of alpha-topography by piracetam in post-stroke aphasia. Int. J. Clin. Pharmacol. Ther., 39, 152-157.
58. VALZELLI, L., BERNASCONI, S. & SALA, A. (1980). Piracetam activity may differ according to the age of the recipient mouse. Int. Pharmacopsychiatry, 15, 150-156.
59. VIEIRA, H. & KROEMER, G. (2003). Mitochondria as targets of apoptosis regulation by nitric oxide. IUBMB Life, 55, 613-616.
60. WAEGEMANS, T., WILSHER, C.R., DANNIAU, A., FERRIS, S.H., KURZ, A. & WINBLAD, B. (2002). Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. Dement. Geriatr. Cogn. Disord., 13, 217-224.
61. WEI, Y.H. & LEE, H.C. (2002). Oxidative stress, mitochondrial DNA mutation, and impairment of antioxidant enzymes in aging. Exp. Biol. Med. (Maywood), 227, 671-682.